ARS Pharmaceuticals
SPRY
ARS Pharmaceuticals (SPRY) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.63
- EPS estimate
- −$0.48
- EPS surprise
- −31.88%
- Revenue surprise
- +7.46%
- Revenue
- $33.7M
- Revenue estimate
- $31.3M
- Reported
- Aug 13, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | −$0.48 | −$0.63 | −31.88% | $33.7M | SEC |
| Q1 2026 | May 15, 2026 | −$0.52 | −$0.61 | −18.22% | $22.7M | SEC |
| Q4 2025 | Mar 9, 2026 | −$0.43 | −$0.41 | +4.63% | $28.1M | SEC |
| Q3 2025 | Nov 10, 2025 | −$0.45 | −$0.52 | −14.59% | $32.5M | SEC |
| Q2 2025 | Aug 13, 2025 | −$0.46 | −$0.46 | −0.41% | $15.7M | SEC |
| Q1 2025 | May 14, 2025 | −$0.34 | −$0.35 | −3.46% | $8.0M | SEC |
| Q4 2024 | Mar 20, 2025 | −$0.24 | $0.48 | +302.11% | $86.6M | SEC |
| Q3 2024 | Nov 13, 2024 | −$0.14 | −$0.20 | −40.35% | $2.1M | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.11 | −$0.13 | −17.54% | $500,000.00 | SEC |
| Q1 2024 | May 9, 2024 | −$0.10 | −$0.11 | −11.22% | $0.00 | SEC |
| Q4 2023 | Mar 21, 2024 | −$0.14 | −$0.07 | +49.05% | $0.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.18 | −$0.16 | +10.01% | $0.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$0.17 | −$0.18 | −7.98% | $10,000.00 | SEC |
| Q1 2023 | May 15, 2023 | −$0.16 | −$0.16 | −2.11% | $20,000.00 | SEC |
| Q4 2022 | Mar 23, 2023 | −$0.13 | −$0.26 | −103.76% | $650,000.00 | SEC |
| Q3 2022 | Nov 2, 2022 | −$0.50 | −$0.50 | +0.00% | $0.00 | — |
| Q1 2022 | May 12, 2022 | −$0.50 | −$0.70 | −41.41% | $0.00 | SEC |
| Q4 2021 | Mar 31, 2022 | −$0.67 | −$0.67 | +0.59% | $0.00 | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.65 | −$0.65 | +0.31% | $0.00 | SEC |
| Q2 2021 | Aug 12, 2021 | −$0.54 | −$0.70 | −30.60% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did ARS Pharmaceuticals (SPRY) last report earnings?
ARS Pharmaceuticals last reported on Aug 13, 2026, covering fiscal Q2 2026.
Did SPRY beat earnings estimates?
No. ARS Pharmaceuticals reported EPS of −$0.63 for Q2 2026 against a −$0.48 estimate — a 31.88% miss.
How much revenue did SPRY report last quarter?
ARS Pharmaceuticals reported $33.7M in revenue for Q2 2026, against a consensus estimate of $31.3M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.